Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

E2IP mandated by CAE to help deliver critical ventilator initiative


MONTREAL, July 9, 2020 /CNW Telbec/ - E2IP TECHNOLOGIES is proud to be one of CAE's suppliers in the manufacturing of the CAE Air1TM ventilator destined to be used in the fight against COVID-19 throughout Canada.

E2IP will be building the mechanical parts of the ventilator from one of its ISO 13485 certified facilities in Montreal which relies on a specialized workforce of 200 employees supporting primary care electronic device design and manufacturing for global medical industry leaders.

"E2IP is a trusted partner in the design and manufacturing of human machine interface solutions for insulin pumps, hospital beds, infusion pumps, and many other primary care medical devices. We are proud to now be working with CAE on the Air1TM ventilator, a critical initiative for communities across Canada," said Steve Birrell, Chief Commercial Officer for E2IP TECHNOLOGIES.

"E2IP was quick to respond to global call for action to address COVID-19 challenges," said Eric Saint-Jacques, CEO of E2IP TECHNOLOGIES. E2IP plants in Montreal, Minnesota and Casablanca, all required to support global medical industry demand, remained at full capacity. Manufacturing operations increased and production lines were reconfigured to produce face shields for communities and governments across North America. Several disruptive innovations were also developed both by the company's industry leading R&D team, and in partnership with the National Research Council of Canada, which will add further depth to the company's broad portfolio of printed electronics intellectual property.

"This project with CAE, and our overall response to the COVID-19 pandemic, speak to E2IP's core pillars of Innovation, Partnership, Operational Excellence and Talent," said M. Saint-Jacques. "We also look forward to further developing our footprint in the global Aerospace market, a market in which we are recognized as a technology and innovation leader, through the integration of our printed electronics technology IP."

CAE is a global leader in training for the civil aviation, defence and security, and healthcare markets. CAE designed the CAE Air1tm ventilator as a humanitarian response to the COVID-19 pandemic. The Government of Canada mandated CAE to manufacture and supply 10,000 ventilators to support Intensive Care Units patients treated for COVID-19. The CAE Air1 ventilator was the first entirely new ventilator to be certified by Health Canada since the beginning of the pandemic.

About E2IP TECHNOLOGIES

E2IP creates new possibilities in printed electronics through advanced material science. Our technologies transform the surfaces we touch in our everyday lives and simplify how we all interact with our physical environment. From ideation to fabrication, we rethink the boundaries between technology and design to deliver innovative Human Machine Interface (HMI) and Smart Surface solutions to global market leaders in the aerospace, medical, industrial and transportation industries.

SOURCE E2IP TECHNOLOGIES


These press releases may also interest you

at 16:10
Aptinyx Inc. , a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2020 and highlighted recent progress...

at 16:10
Urovant Sciences today reported financial results for the three months ended June 30, 2020. The first quarter of fiscal 2020 saw the Company achieve a number of significant operational milestones as it embarked on the build out of both its...

at 16:10
CynergisTek, Inc. , a leader in cybersecurity, privacy, and compliance, today announced financial results for the three and six months ended June 30, 2020. Recent Operational Focus due to COVID-19 Includes: Won two large Fortune 1,000 and Global...

at 16:10
Repare Therapeutics Inc. ("Repare") , a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results for the second quarter ended...

at 16:10
Navidea Biopharmaceuticals, Inc. ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and year-to-date for the...

at 16:07
Regulus Therapeutics Inc. , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the second  quarter ended June 30, 2020...



News published on 9 july 2020 at 06:00 and distributed by: